Sitagliptin (Januvia) Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans

Trial Profile

Sitagliptin (Januvia) Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans

Completed
Phase of Trial: Phase II/III

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Hyperlipidaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top